Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.
about
Association of breast cancer risk and the mTOR pathway in women of African ancestry in 'The Root' Consortium.RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.Dehydroabietic oximes halt pancreatic cancer cell growth in the G1 phase through induction of p27 and downregulation of cyclin D1
P2860
Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.
description
2016 nî lūn-bûn
@nan
2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.
@ast
Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.
@en
type
label
Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.
@ast
Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.
@en
prefLabel
Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.
@ast
Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.
@en
P2093
P2860
P50
P1476
Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.
@en
P2093
George A O'Doherty
J Preston Campbell
Katarzyna A Ludwik
Lejla Pasic
Mingzong Li
Miranda E Sowder
P2860
P304
P356
10.1158/1535-7163.MCT-16-0106
P577
2016-08-15T00:00:00Z